Rezolute, Inc. Form 8-K Summary
Business Context and Reporting Period
Rezolute, Inc. (Delaware) filed this Current Report on Form 8-K on April 3, 2018, regarding events occurring on April 2, 2018. The filing details the completion of a second closing on a convertible note financing (Debt Financing) and the entry into a material definitive agreement with a placement agent.
Key Financial Metrics
- Gross Proceeds: $4.0 million received from the second closing of the Debt Financing (excluding transaction costs, fees, and expenses).
- Debt Instrument: Secured convertible promissory note bearing 12% annual interest.
- Maturity Date: January 31, 2019 (payable in a single cash payment).
- Security: Notes are secured by a perfected security interest in the Company's tangible assets.
- Placement Agent Fees: 7% cash fee of gross proceeds plus a warrant equal to 10% of gross proceeds.
- Liquidity: The filing does not provide specific cash balance or liquidity metrics beyond the proceeds received.
Material Changes and Terms
The Company amended initial investments of $700,000 to align with the terms of the new closing. Key terms of the financing include:
- Conversion Trigger: The Note converts into equity upon a "Qualified Financing" (aggregate gross proceeds of at least $15 million) at a 20% discount.
- Warrant Terms: Investors received warrants to purchase shares equal to 100% of the shares the Notes would convert into (if Qualified Financing occurs before July 1, 2018) or based on principal divided by weighted average price (if no Qualified Financing by July 1, 2018).
- Warrant Exercise Price: Set at 120% of the per-share price of stock issued in a Qualified Financing or 120% of the weighted average price if no Qualified Financing occurs by July 1, 2018.
Outlook, Management Commentary, and Risks
Management stated the Debt Financing is critical to support ongoing operations while preparing for a Qualified Financing targeted for completion prior to the end of Q2 2018. Proceeds from a future Qualified Financing are intended to:
- Commence a Phase 2b study for RZ358 in Europe and the US.
- Complete the ongoing Phase 1 study in the US for AB101.
- Finalize preclinical tasks and file an Investigational New Drug (IND) application for RZ402.
Risks and Contingencies: The Company faces a liquidity contingency if a Qualified Financing is not secured by the maturity date (January 31, 2019) or the warrant pricing deadline (July 1, 2018). The securities were issued under Section 4(a)(2) and Rule 506 exemptions, meaning they cannot be resold in the US without registration.
Investor Verification Checklist
- Verify the Company's ability to secure a $15 million Qualified Financing before July 1, 2018, to trigger favorable conversion terms.
- Confirm the Company's cash runway to meet the January 31, 2019, maturity date if a Qualified Financing is delayed.
- Review the full text of the Note (Exhibit 10.1) and Warrant (Exhibit 4.1) for specific dilution mechanics and adjustment provisions.
- Assess the impact of the 7% cash fee and 10% warrant fee paid to the placement agent on net proceeds.